Medicare Part B Drugs: Feds Keep Most Favored Nation Drug Model on Hold

Why This Topic Matters

The discussion helps readers understand why a major Medicare Part B drug pricing initiative was paused and what regulatory factors may influence future policy. It is useful for organizations monitoring CMS rulemaking, litigation impacts, and drug reimbursement policy changes.

Article Sections

1. Background

   Provides the regulatory and policy context for the Medicare Part B drug pricing model and the agency’s proposed change. It also introduces the broader Medicare and executive-order setting.

2. Here’s Why the Feds Halted the MFN Model Rollout

   Summarizes stakeholder response, legal activity, and procedural issues that affected implementation of the model. It also describes the agency’s stated reasons for reconsidering the policy.

3. Timeline

   Gives the comment deadline associated with the proposal.

4. Resources

   Lists source documents and reference links related to the rulemaking and executive order.